Rogaratinib

Rogaratinib (BAY-1163877) is a highly potent and selective small molecule inhibitor of pan‐FGFR kinase activity, which specifically inhibits FGFR1, 2, 3 and 4 with an IC50 values of 1.8 nM, <1 nM, 9.2 nM and 1.2 nM respectively. It demonstrates robust efficacy in cancers with altered FGFR mRNA expression.